These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29940415)

  • 61. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
    Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
    Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Status and challenges of filovirus vaccines.
    Reed DS; Mohamadzadeh M
    Vaccine; 2007 Mar; 25(11):1923-34. PubMed ID: 17241710
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
    Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
    Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The role of reverse genetics systems in determining filovirus pathogenicity.
    Theriault S; Groseth A; Artsob H; Feldmann H
    Arch Virol Suppl; 2005; (19):157-77. PubMed ID: 16355872
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine.
    Theiler J; Yoon H; Yusim K; Picker LJ; Fruh K; Korber B
    Sci Rep; 2016 Oct; 6():33987. PubMed ID: 27703185
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
    Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
    Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development and Structural Analysis of Antibody Therapeutics for Filoviruses.
    Yu X; Saphire EO
    Pathogens; 2022 Mar; 11(3):. PubMed ID: 35335698
    [TBL] [Abstract][Full Text] [Related]  

  • 68. First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain.
    Ramírez de Arellano E; Sanchez-Lockhart M; Perteguer MJ; Bartlett M; Ortiz M; Campioli P; Hernández A; Gonzalez J; Garcia K; Ramos M; Jiménez-Clavero MÁ; Tenorio A; Sánchez-Seco MP; González F; Echevarría JE; Palacios G; Negredo A
    Viruses; 2019 Apr; 11(4):. PubMed ID: 31010201
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Suspected Exposure to Filoviruses Among People Contacting Wildlife in Southwestern Uganda.
    Smiley Evans T; Tutaryebwa L; Gilardi KV; Barry PA; Marzi A; Eberhardt M; Ssebide B; Cranfield MR; Mugisha O; Mugisha E; Kellermann S; Mazet JAK; Johnson CK
    J Infect Dis; 2018 Nov; 218(suppl_5):S277-S286. PubMed ID: 29924324
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evidence for occurrence of filovirus antibodies in humans and imported monkeys: do subclinical filovirus infections occur worldwide?
    Becker S; Feldmann H; Will C; Slenczka W
    Med Microbiol Immunol; 1992; 181(1):43-55. PubMed ID: 1579085
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Crystal structure of the Měnglà virus VP30 C-terminal domain.
    Dong S; Wen K; Chu H; Li H; Yu Q; Wang C; Qin X
    Biochem Biophys Res Commun; 2020 Apr; 525(2):392-397. PubMed ID: 32093889
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Filovirus entry into cells - new insights.
    Miller EH; Chandran K
    Curr Opin Virol; 2012 Apr; 2(2):206-14. PubMed ID: 22445965
    [TBL] [Abstract][Full Text] [Related]  

  • 73. "Filoviruses": a real pandemic threat?
    Martina BE; Osterhaus AD
    EMBO Mol Med; 2009 Apr; 1(1):10-8. PubMed ID: 20049699
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.
    de La Vega MA; Xiii A; Massey S; Spengler JR; Kobinger GP; Woolsey C
    Expert Opin Drug Discov; 2024 Oct; 19(10):1185-1211. PubMed ID: 39090822
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An interagency collaboration to facilitate development of filovirus medical countermeasures.
    Kilgore N; Nuzum EO
    Viruses; 2012 Oct; 4(10):2312-6. PubMed ID: 23202465
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tissue factor initiation of disseminated intravascular coagulation in filovirus infection.
    Grob C
    Med Hypotheses; 1995 Oct; 45(4):380-2. PubMed ID: 8577301
    [TBL] [Abstract][Full Text] [Related]  

  • 77. AAV Vectored Immunoprophylaxis for Filovirus Infections.
    Rghei AD; van Lieshout LP; Santry LA; Guilleman MM; Thomas SP; Susta L; Karimi K; Bridle BW; Wootton SK
    Trop Med Infect Dis; 2020 Nov; 5(4):. PubMed ID: 33182447
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A call to action to enhance filovirus disease outbreak preparedness and response.
    Roddy P
    Viruses; 2014 Sep; 6(10):3699-718. PubMed ID: 25271875
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutics Against Filovirus Infection.
    Connor J; Kobinger G; Olinger G
    Curr Top Microbiol Immunol; 2017; 411():263-290. PubMed ID: 28653190
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Filoviruses: Interactions with the host cell.
    Dolnik O; Kolesnikova L; Becker S
    Cell Mol Life Sci; 2008 Mar; 65(5):756-76. PubMed ID: 18158582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.